Companies /Healthcare
Envista Holdings Corp
NYSE: NVST Medical Instruments & Supplies
$23.19
▲ $0.22 (+0.96%) today
Markets closed · 10:25pm ET

Envista (NVST) Q3 2025 Earnings

Reported Oct 29, 2025, 4:57pm ET · SEC source
$0.32
Beat +15.94%
EPS · est. $0.28
$669.9M
Beat +4.55%
Revenue · est. $640.8M
−0.0%
Trailing market
NVST vs S&P since report
5 quarters
Consecutive EPS beats

How Did NVST Stock React to Q3 2025 Earnings?

% change · around the report
−6%−4%−2%0Oct 29Oct 30report 4:57pm ETearnings−0.6%−3.6%
−6%−4%−2%0Oct 29Oct 30earnings−0.6%−3.6%
NVST −3.6%S&P 500 −0.6%
−6%−4%−2%0Oct 29Oct 30report 4:57pm ETearnings−0.9%−3.6%
−6%−4%−2%0Oct 29Oct 30earnings−0.9%−3.6%
NVST −3.6%NASDAQ −0.9%
−6%−3%0+3%Oct 28Nov 6report 4:57pm ETearnings−2.1%−6.8%
−6%−3%0+3%Oct 28Nov 6earnings−2.1%−6.8%
NVST −6.8%S&P 500 −2.1%
−6%−3%0+3%Oct 28Nov 6report 4:57pm ETearnings−3.4%−6.8%
−6%−3%0+3%Oct 28Nov 6earnings−3.4%−6.8%
NVST −6.8%NASDAQ −3.4%
+0.80%
Day of report
+1.04%
Next session
−3.28%
One week
+0.20%
30 days

S&P 500 over the same 30 days: +0.25%.

Did NVST Beat Earnings? Q3 2025 Results

Yes. Envista reported Q3 2025 earnings of $0.32 a share on Oct 29, 2025, beating the $0.28 consensus estimate by 15.9%. Revenue was $669.9M against a $640.8M estimate.

Envista Holdings posted a convincing beat across the board in the third quarter of fiscal 2025, with adjusted diluted EPS of $0.32 clearing the $0.28 consensus estimate by 15.94% and revenue of $669.90 million topping expectations by 4.55% on 11.5% year-over-year growth. The primary engine behind the quarter's strength was the Specialty Products & Technologies segment, which grew total sales 13.0% to $431.50 million, while Equipment & Consumables contributed 8.7% growth to $238.40 million, together reflecting broad-based momentum across the dental portfolio. Profitability expanded sharply, with adjusted EBITDA rising 77% to $97.10 million and adjusted EBITDA margin widening 540 basis points to 14.5%. A GAAP net loss of $30.30 million, driven by a $61.20 million discrete tax charge from intercompany loan restructuring, obscured the underlying operating progress. Management responded to the quarter's performance by raising full-year core sales growth guidance to approximately 4% and tightening adjusted diluted EPS guidance to $1.10 to $1.15, though some analysts flag potential headwinds from China's next round of volume-based procurement into 2026.

Key Takeaways
  • Core sales growth of 9.4% in Q3 2025
  • All major businesses delivered positive growth
  • Spark aligners captured market share and achieved positive operating margin
  • Envista Business System (EBS) drove broad-based operational contributions
  • Specialty Products & Technologies segment posted 10.6% core sales growth
  • Adjusted EBITDA margin expanded 540 bps year-on-year to 14.5%
  • Adjusted gross margin improved to 56.1% from 52.8%

“This was another strong quarter for Envista, with core growth, adjusted EBITDA, and adjusted EPS all ahead of expectations.”

Envista CEO, on the earnings call

What Was Envista's Outlook in Q3 2025?

Envista updated its full-year 2025 guidance, raising core sales growth expectations to approximately 4% (from 3% to 4% previously), maintaining adjusted EBITDA margin at approximately 14%, and narrowing/raising adjusted diluted EPS guidance to $1.10 to $1.15 (from $1.05 to $1.15 previously).

NVST YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$200.0M$400.0M$600.0M$601.0M$669.9MRevenue$317.4M$370.2MGross Profit$20.9M$57.5MOperating Income
$0$200.0M$400.0M$600.0MRevenueGross ProfitOperating Income
NVST income statement, Q3 2025 versus Q3 2024
Metric Q3 2025 Q3 2024 Year over year
Revenue $669.9M $601.0M +11.5%
Gross Profit $370.2M $317.4M +16.6%
Operating Income $57.5M $20.9M +175.1%

NVST Revenue by Segment

Specialty Products & Technologies$431.5M+13.0%
Equipment & Consumables$238.4M+8.7%

Figures from SEC filings and company reports. Not investment advice.